Primary treatment of Crohn’s disease: combined antibiotics taking center stage

  title={Primary treatment of Crohn’s disease: combined antibiotics taking center stage},
  author={William M. Chamberlin and Thomas J. Borody and Jordana Campbell},
  journal={Expert Review of Clinical Immunology},
  pages={751 - 760}
Although controversial, the use of properly chosen antibiotics in Crohn's disease appears beneficial. [] Key Method Relevant studies identified through a Medline search from 1976 to 2011 were assessed for inclusion by two independent observers who resolved any disagreements by consensus. References from all identified articles and recent review articles were cross-checked to ensure a thorough search. Papers were selected based on scientific merit as to which presented original contributions to the results.
Profound remission in Crohn’s disease requiring no further treatment for 3–23 years: a case series
Prolonged remission has been achieved for 3–23 years with individualised treatments, with the majority using AMAT ± infliximab and FMT.
A Therapeutic Role for Diet in the Treatment of Crohn’s Disease?
The argument is presented that specifically targeted dietary supplementation may be necessary to treat Crohn’s disease through the correction of diseased induced impairment of host immunity.
Crohn’s Disease: A Curable Disease Held Hostage?
  • G. Monif
  • Medicine
    Academic Journal of Gastroenterology & Hepatology
  • 2019
FDA’s reliance on clinical validation must through comparative, placebo controlled, double-blinded studies has created an impediment to acceptance of divergent alternated therapies as being within the standard of care.
A Potential ‘Curative’ Modality for Crohn’s Disease---Modeled after Prophylaxis of Bovine Johne’s Disease
  • R. E. Click
  • Medicine
    Mycobacterial diseases : tuberculosis & leprosy
  • 2012
A naturally occurring, gastrointestinal disorder of ruminants (Johne’s disease) is a chronic, debilitating, lethal disease. The causative agent is Mycobacterium avium subspecies paratuberculosis
Putting Crohn’s on the MAP: Five Common Questions on the Contribution of Mycobacterium avium subspecies paratuberculosis to the Pathophysiology of Crohn’s Disease
The authors hope that this discussion will stimulate further research aimed at confirming or refuting the contribution of MAP to the pathogenesis of Crohn’s disease and ultimately lead to advanced targeted clinical therapies.
Combining infliximab, anti-MAP and hyperbaric oxygen therapy for resistant fistulizing Crohn's disease
Combining infliximab, hyperbaric oxygen therapy and anti-MAP seems to enable healing of recalcitrant fistulae and although a small case series, all nine patients achieved complete healing.
Resolution of Crohn’s (Johne’s) disease with antibiotics: what are the next steps?
Observations indicate that infection with Map is similar to tuberculosis in which the majority of subjects infected with M. tuberculosis develop a protective immune response that controls but does not eliminate the pathogen.
The Changing Face of Inflammatory Bowel Disease: Etiology, Physiopathology, Epidemiology
A multidisciplinary approach will soon be necessary, to face the tenacious behavior of IBD, on a global perspective.
Comment on 2018 ACG Clinical Guideline: Antibiotics in Crohn’s Disease
The ACG recently released the 2018 Guidelines for Crohn’s Disease are incorrect on several points regarding mycobacteria, according to a report published in the Annals of Internal Medicine.
Molecular analysis of sarcoidosis lymph nodes for microorganisms: a case–control study with clinical correlates
It is suggested that bacterial DNA-positive, symptomatic patients have more aggressive sarcoidosis that persists long term and might benefit from antimicrobial treatment directed against this presumed chronic granulomatous infection.


Preliminary Study of Ciprofloxacin in Active Crohn's Disease
It is suggested that ciprofloxacin may be an effective agent when added to the treatment of moderately active, resistant CD and disease remission is defined as a decrease in the CDAI score to less than 150 points.
Long-term antibiotic treatment for Crohn's disease: systematic review and meta-analysis of placebo-controlled trials.
Long-term treatment with nitroimidazoles or clofazimine appears to be effective in patients with Crohn's disease.
Antibiotic Therapy in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis
Antibiotic therapy may induce remission in active CD and UC, although the diverse number of antibiotics tested means the data are difficult to interpret.
Combined budesonide and antibiotic therapy for active Crohn's disease: a randomized controlled trial.
In patients with active Crohn's disease of the ileum, the addition of ciprofloxacin and metronidazole to budesonide is an ineffective intervention, but this antibiotic combination may improve outcome when there is involvement of the colon.
Treatment of severe Crohn's disease using antimycobacterial triple therapy--approaching a cure?
  • T. Borody, S. Leis, E. Warren, R. Surace
  • Medicine, Biology
    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
  • 2002
Use of antibiotics in the treatment of active Crohn's disease: experience with metronidazole and ciprofloxacin.
Metronidazole and ciprofloxacin seem to be useful in treating active phases of Crohn's disease, and these results strongly support the important role of faecal flora in causing Cro bowel disease symptoms.
Antimycobacterial therapy in Crohn's disease: results of a controlled, double-blind trial with a multiple antibiotic regimen.
This study suggests that the treatment regimen with rifampicin, ethambutol, clofazimine, and dapsone is effective in relief of symptoms and maintenance of remission in some Crohn's disease patients.
Is there a role for antibiotics as primary therapy in Crohn's ileitis?
There is a need for a prospective controlled trial of ciprofloxacin or other antibiotics in active Crohn's ileitis, according to each patient, which had a dramatic improvement in abdominal pain and diarrhea coincident with the institution of cIProfl oxacin.
An antibiotic regimen for the treatment of active Crohn's disease: a randomized, controlled clinical trial of metronidazole plus ciprofloxacin.
OBJECTIVES Bacteria in the gut lumen may play a role in the etiology and/or the symptoms of Crohn's disease (CD). Although various antibacterial drugs have been employed in clinical practice, few